Clinical Trial Hopes to Boost Survival Rates with Personalized Treatment for Extensive-Stage Small Cell Lung Cancer
Sacituzumab govitecan (SG) is being evaluated versus topotecan as a second‑line treatment for patients with previously treated extensive‑stage small cell lung cancer (ES‑SCLC).
This PDQ cancer information summary for health professionals provides comprehensive, peer‑reviewed, evidence‑based information about the treatment of small‑cell lung cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.
Providing a new, potentially more effective treatment option for ES‑SCLC, where second‑line therapies are currently limited.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells